In current work, we will evaluate the expression and role of circulating exosomal miR‐16‐5p in LUAD sufferers and cultured tumor cells and investigate whether serum exosomal miR‐16‐5p can be utilized as a biomarker to identify LUAD sufferers suitable for PD‐L1 inhibitor treatment. The gene discussed is CD274; the disease is neoplasm.